Table 1

Patients’ characteristics

Discovery cohortValidation cohort
nSS /iSS (n=6/2)pSS
(n=8)
nSS
(n=17)
iSS
(n=16)
pSS
(n=24)
Female gender, n (%)8 (100)7 (88)15 (88)14 (88)21 (88)
Age, years (mean±SD)50±1751±1349±1654±1555±12
Anti-Ro/SSA+, n (%)2 (25)6 (75)0 (0)10 (63)16 (67)
Anti-La/SSB+, n (%)0 (0)2 (25)0 (0)0 (0)4 (17)
ANA+, n (%)3 (38)6 (75)9 (53)7 (44)17 (71)
RF+, n (%)0 (0)3 (37.5)0 (0)1 (6)8 (33)
Lymphocytic focus score (foci/4 mm2)0 (0–0)1.8 (1.0–2.4)0 (0–0)0.2 (0–0.7)1.6 (1.0–2.6)
IgA+plasma cells (%)73(70–80)62 (45–67)77 (71–80)70 (68–76)59 (49–64)
Schirmer (mm/5 min)2 (0–11)7 (1–25)4 (1–7)10 (2–13)7 (3–11)
Serum IgG (g/L)10.8 (7.6–14.2)14.4 (11.8–19.0)11.0 (6.5–12.3)9.0 (8.0–13.6)13.9 (10.1–18.3)
ESR (mm/hour)7 (5–12)13 (7–50)7 (6–10)9 (5–15)15 (7–29)
ESSDAI score (0–123)NA2 (0–6)NANA3 (1–7)
ESSPRI score (0–10)NA3.5 (1.6–5.4)NANA5.3 (2.3–6.0)
Immunosuppressants, n (%)1 (12.5)1 (12.5)1 (6)2 (13)3 (12.5)
  • Median with IQR are represented, unless specified otherwise.

  • ESR, erythrocyte sedimentation rate; ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren’s Syndrome Patient Reported Index; RF, rheumatoid factor; SSA, Sjögren’s syndrome antigen A; SSB, Sjögren’s syndrome antigen B; iSS, incomplete Sjögren’s syndrome; nSS, non-Sjögren’s sicca; pSS, primary Sjögren’s syndrome.